Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 63 | 2024 | 1296 | 8.700 |
Why?
|
Tissue and Organ Procurement | 19 | 2023 | 340 | 4.800 |
Why?
|
Kidney Transplantation | 21 | 2024 | 849 | 4.360 |
Why?
|
Tissue Donors | 23 | 2024 | 496 | 3.750 |
Why?
|
Graft Survival | 37 | 2024 | 911 | 3.590 |
Why?
|
Kidney Failure, Chronic | 6 | 2023 | 412 | 1.800 |
Why?
|
Graft Rejection | 15 | 2019 | 1083 | 1.530 |
Why?
|
Waiting Lists | 10 | 2023 | 188 | 1.480 |
Why?
|
Liver Failure | 7 | 2023 | 81 | 1.460 |
Why?
|
Hepatitis C | 7 | 2019 | 219 | 1.270 |
Why?
|
End Stage Liver Disease | 4 | 2024 | 71 | 1.220 |
Why?
|
Living Donors | 9 | 2024 | 344 | 1.170 |
Why?
|
Liver Diseases | 6 | 2020 | 250 | 1.130 |
Why?
|
Carcinoma, Hepatocellular | 6 | 2012 | 404 | 1.110 |
Why?
|
Liver Cirrhosis | 5 | 2014 | 305 | 1.050 |
Why?
|
Kidney | 5 | 2023 | 1145 | 1.020 |
Why?
|
Retrospective Studies | 38 | 2024 | 8860 | 1.000 |
Why?
|
Survival Rate | 19 | 2020 | 1881 | 0.990 |
Why?
|
Liver Neoplasms | 6 | 2012 | 768 | 0.950 |
Why?
|
Liver Failure, Acute | 3 | 2009 | 39 | 0.880 |
Why?
|
T-Lymphocytes, Regulatory | 4 | 2013 | 302 | 0.810 |
Why?
|
Death | 6 | 2020 | 84 | 0.810 |
Why?
|
Humans | 88 | 2024 | 88416 | 0.800 |
Why?
|
Liver | 10 | 2021 | 1241 | 0.750 |
Why?
|
Risk Factors | 19 | 2024 | 5434 | 0.730 |
Why?
|
Risk Assessment | 11 | 2020 | 2285 | 0.690 |
Why?
|
Postoperative Complications | 7 | 2012 | 2280 | 0.660 |
Why?
|
Forkhead Transcription Factors | 3 | 2013 | 171 | 0.660 |
Why?
|
Portal Vein | 3 | 2010 | 119 | 0.650 |
Why?
|
Male | 51 | 2024 | 41926 | 0.650 |
Why?
|
Transplantation, Homologous | 8 | 2010 | 1001 | 0.650 |
Why?
|
Adult | 34 | 2024 | 26280 | 0.650 |
Why?
|
Liver Circulation | 2 | 2010 | 30 | 0.640 |
Why?
|
Transplant Recipients | 1 | 2020 | 139 | 0.640 |
Why?
|
Follow-Up Studies | 14 | 2020 | 3652 | 0.620 |
Why?
|
Female | 51 | 2024 | 45652 | 0.610 |
Why?
|
Models, Statistical | 2 | 2013 | 575 | 0.600 |
Why?
|
Obesity | 4 | 2024 | 968 | 0.600 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2009 | 1348 | 0.590 |
Why?
|
Fatty Liver | 3 | 2010 | 132 | 0.580 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 743 | 0.560 |
Why?
|
Immune Tolerance | 3 | 2013 | 338 | 0.560 |
Why?
|
Patient Selection | 6 | 2012 | 689 | 0.540 |
Why?
|
Transplantation Tolerance | 2 | 2008 | 134 | 0.530 |
Why?
|
Middle Aged | 34 | 2024 | 25626 | 0.530 |
Why?
|
Aged | 22 | 2024 | 18887 | 0.530 |
Why?
|
Treatment Outcome | 21 | 2024 | 8139 | 0.520 |
Why?
|
Dendritic Cells | 3 | 2013 | 436 | 0.520 |
Why?
|
Severity of Illness Index | 9 | 2023 | 1841 | 0.510 |
Why?
|
Donor Selection | 3 | 2020 | 73 | 0.500 |
Why?
|
Child, Preschool | 14 | 2024 | 3669 | 0.490 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 3 | 2013 | 36 | 0.470 |
Why?
|
Child | 17 | 2024 | 7079 | 0.460 |
Why?
|
Length of Stay | 3 | 2013 | 726 | 0.460 |
Why?
|
Hepatic Artery | 3 | 2012 | 85 | 0.450 |
Why?
|
Adolescent | 18 | 2024 | 9135 | 0.440 |
Why?
|
Prognosis | 11 | 2019 | 3747 | 0.440 |
Why?
|
Polymorphism, Genetic | 2 | 2006 | 824 | 0.420 |
Why?
|
Graft vs Host Disease | 2 | 2021 | 358 | 0.410 |
Why?
|
Hepacivirus | 6 | 2019 | 165 | 0.400 |
Why?
|
United States | 14 | 2023 | 6872 | 0.400 |
Why?
|
Perfusion | 2 | 2020 | 226 | 0.400 |
Why?
|
Health Status Indicators | 1 | 2012 | 104 | 0.400 |
Why?
|
Thinness | 2 | 2010 | 43 | 0.390 |
Why?
|
Infant | 13 | 2024 | 3111 | 0.390 |
Why?
|
Reoperation | 5 | 2023 | 605 | 0.390 |
Why?
|
Survival Analysis | 6 | 2014 | 1542 | 0.370 |
Why?
|
Antigens, CD | 3 | 2008 | 465 | 0.370 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2010 | 8 | 0.370 |
Why?
|
Cause of Death | 4 | 2020 | 270 | 0.370 |
Why?
|
Critical Care | 2 | 2020 | 377 | 0.360 |
Why?
|
Biopsy, Needle | 3 | 2012 | 235 | 0.350 |
Why?
|
Drug Monitoring | 1 | 2010 | 119 | 0.340 |
Why?
|
Adoptive Transfer | 2 | 2006 | 169 | 0.340 |
Why?
|
Preoperative Care | 2 | 2009 | 398 | 0.340 |
Why?
|
Renal Dialysis | 2 | 2024 | 335 | 0.340 |
Why?
|
Acetaminophen | 2 | 2006 | 55 | 0.330 |
Why?
|
Prospective Studies | 8 | 2018 | 4265 | 0.330 |
Why?
|
Multivariate Analysis | 6 | 2019 | 994 | 0.330 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2009 | 37 | 0.330 |
Why?
|
Body Mass Index | 4 | 2024 | 767 | 0.320 |
Why?
|
Fatigue | 1 | 2009 | 178 | 0.320 |
Why?
|
Constriction, Pathologic | 2 | 2006 | 218 | 0.320 |
Why?
|
Medical Errors | 1 | 2009 | 116 | 0.320 |
Why?
|
Thrombosis | 2 | 2012 | 301 | 0.310 |
Why?
|
Young Adult | 11 | 2020 | 6189 | 0.310 |
Why?
|
Transplants | 2 | 2018 | 42 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 5 | 2024 | 863 | 0.300 |
Why?
|
Time Factors | 10 | 2019 | 5302 | 0.300 |
Why?
|
Proportional Hazards Models | 8 | 2024 | 858 | 0.290 |
Why?
|
Incidence | 8 | 2019 | 1588 | 0.290 |
Why?
|
Lymphocytic choriomeningitis virus | 1 | 2006 | 13 | 0.280 |
Why?
|
Lymphocytic Choriomeningitis | 1 | 2006 | 8 | 0.280 |
Why?
|
Compartment Syndromes | 1 | 2006 | 13 | 0.280 |
Why?
|
Aged, 80 and over | 5 | 2023 | 6706 | 0.280 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2006 | 12 | 0.280 |
Why?
|
Hepatitis | 1 | 2006 | 35 | 0.280 |
Why?
|
Biliary Atresia | 1 | 2006 | 23 | 0.280 |
Why?
|
Aprotinin | 1 | 2006 | 26 | 0.280 |
Why?
|
Liver Regeneration | 1 | 2006 | 37 | 0.280 |
Why?
|
Survival | 1 | 2006 | 21 | 0.280 |
Why?
|
Catheter Ablation | 1 | 2009 | 251 | 0.280 |
Why?
|
Delayed Graft Function | 2 | 2020 | 13 | 0.280 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2006 | 28 | 0.280 |
Why?
|
Bile Ducts | 1 | 2006 | 59 | 0.280 |
Why?
|
Mannose-Binding Lectin | 1 | 2006 | 3 | 0.280 |
Why?
|
Cholecystectomy | 1 | 2006 | 19 | 0.270 |
Why?
|
Antigens, Differentiation | 1 | 2006 | 141 | 0.270 |
Why?
|
Hemochromatosis | 1 | 2006 | 11 | 0.270 |
Why?
|
Ferric Compounds | 1 | 2006 | 38 | 0.270 |
Why?
|
Abdomen | 1 | 2006 | 121 | 0.270 |
Why?
|
Hemostatics | 1 | 2006 | 57 | 0.270 |
Why?
|
Staining and Labeling | 1 | 2006 | 167 | 0.270 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2006 | 55 | 0.260 |
Why?
|
Antigen-Presenting Cells | 1 | 2006 | 141 | 0.260 |
Why?
|
Exercise Therapy | 1 | 2006 | 80 | 0.260 |
Why?
|
Ascites | 1 | 2006 | 58 | 0.260 |
Why?
|
Lymphoproliferative Disorders | 1 | 2006 | 111 | 0.260 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2006 | 52 | 0.260 |
Why?
|
Quality of Health Care | 2 | 2006 | 383 | 0.260 |
Why?
|
Viral Envelope Proteins | 1 | 2006 | 95 | 0.260 |
Why?
|
Brain Death | 5 | 2020 | 80 | 0.260 |
Why?
|
Albumins | 1 | 2006 | 130 | 0.260 |
Why?
|
Hepatitis B | 1 | 2006 | 76 | 0.260 |
Why?
|
Steroids | 1 | 2006 | 175 | 0.260 |
Why?
|
Immune System | 1 | 2006 | 97 | 0.260 |
Why?
|
Surgical Mesh | 1 | 2006 | 121 | 0.250 |
Why?
|
Hepatocytes | 1 | 2006 | 127 | 0.250 |
Why?
|
Th2 Cells | 1 | 2006 | 147 | 0.250 |
Why?
|
Herniorrhaphy | 1 | 2006 | 87 | 0.250 |
Why?
|
Serotonin | 1 | 2006 | 220 | 0.250 |
Why?
|
Vascular Diseases | 1 | 2006 | 117 | 0.250 |
Why?
|
Infant, Newborn | 6 | 2024 | 2441 | 0.250 |
Why?
|
Intubation, Intratracheal | 1 | 2006 | 145 | 0.250 |
Why?
|
Metabolic Syndrome | 1 | 2006 | 129 | 0.240 |
Why?
|
HLA Antigens | 1 | 2006 | 226 | 0.240 |
Why?
|
Bacterial Infections | 1 | 2006 | 184 | 0.240 |
Why?
|
Endothelium, Vascular | 1 | 2006 | 433 | 0.230 |
Why?
|
Palliative Care | 1 | 2006 | 264 | 0.230 |
Why?
|
Stents | 1 | 2006 | 390 | 0.230 |
Why?
|
Liver Function Tests | 4 | 2010 | 93 | 0.230 |
Why?
|
Critical Illness | 1 | 2006 | 304 | 0.220 |
Why?
|
Body Surface Area | 1 | 2023 | 36 | 0.220 |
Why?
|
Intention to Treat Analysis | 1 | 2023 | 69 | 0.220 |
Why?
|
Immunity, Innate | 1 | 2006 | 427 | 0.220 |
Why?
|
Organ Transplantation | 1 | 2006 | 276 | 0.210 |
Why?
|
Mice, Inbred C3H | 3 | 2008 | 371 | 0.210 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 994 | 0.210 |
Why?
|
Policy | 1 | 2022 | 35 | 0.210 |
Why?
|
Cohort Studies | 7 | 2020 | 2832 | 0.210 |
Why?
|
Tomography, X-Ray Computed | 2 | 2009 | 2631 | 0.210 |
Why?
|
Residence Characteristics | 1 | 2024 | 194 | 0.210 |
Why?
|
Proteome | 2 | 2014 | 130 | 0.200 |
Why?
|
Geography | 1 | 2022 | 228 | 0.200 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 577 | 0.190 |
Why?
|
Insulin | 1 | 2006 | 1153 | 0.190 |
Why?
|
Hypertension | 1 | 2006 | 730 | 0.190 |
Why?
|
Health Policy | 1 | 2022 | 185 | 0.180 |
Why?
|
Social Class | 1 | 2020 | 134 | 0.180 |
Why?
|
Washington | 3 | 2024 | 49 | 0.180 |
Why?
|
Age Factors | 6 | 2024 | 1859 | 0.170 |
Why?
|
Cold Ischemia | 3 | 2010 | 18 | 0.170 |
Why?
|
Databases, Factual | 4 | 2019 | 846 | 0.170 |
Why?
|
Insurance, Health | 1 | 2020 | 160 | 0.170 |
Why?
|
Mice | 7 | 2013 | 11696 | 0.170 |
Why?
|
Laparoscopy | 1 | 2006 | 762 | 0.160 |
Why?
|
Body Weight | 3 | 2010 | 452 | 0.160 |
Why?
|
Terminal Care | 1 | 2020 | 137 | 0.160 |
Why?
|
Health Status Disparities | 1 | 2020 | 180 | 0.160 |
Why?
|
Hepatitis C Antibodies | 1 | 2018 | 8 | 0.160 |
Why?
|
Tacrolimus | 2 | 2010 | 374 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 2 | 2008 | 2322 | 0.150 |
Why?
|
Predictive Value of Tests | 3 | 2008 | 1704 | 0.150 |
Why?
|
Quality Control | 1 | 2018 | 116 | 0.150 |
Why?
|
Blood Flow Velocity | 2 | 2010 | 199 | 0.150 |
Why?
|
Medicaid | 1 | 2020 | 228 | 0.150 |
Why?
|
Animals | 9 | 2013 | 27171 | 0.150 |
Why?
|
Histocompatibility Testing | 2 | 2008 | 138 | 0.150 |
Why?
|
Antilymphocyte Serum | 1 | 1997 | 71 | 0.150 |
Why?
|
Muromonab-CD3 | 1 | 1997 | 69 | 0.150 |
Why?
|
Logistic Models | 3 | 2010 | 1204 | 0.150 |
Why?
|
Erythrocyte Transfusion | 1 | 2018 | 72 | 0.150 |
Why?
|
CTLA-4 Antigen | 2 | 2008 | 138 | 0.140 |
Why?
|
Probability | 2 | 2009 | 356 | 0.140 |
Why?
|
Intestines | 2 | 2010 | 415 | 0.140 |
Why?
|
Cell Transplantation | 2 | 2006 | 47 | 0.140 |
Why?
|
Needs Assessment | 2 | 2009 | 158 | 0.140 |
Why?
|
Mice, Inbred Strains | 2 | 2006 | 307 | 0.130 |
Why?
|
Glucose Tolerance Test | 2 | 2006 | 227 | 0.130 |
Why?
|
Healthcare Disparities | 1 | 2020 | 394 | 0.130 |
Why?
|
Proteomics | 2 | 2014 | 227 | 0.130 |
Why?
|
Registries | 3 | 2010 | 753 | 0.120 |
Why?
|
Case-Control Studies | 1 | 2018 | 1848 | 0.110 |
Why?
|
CD4 Antigens | 1 | 2013 | 83 | 0.110 |
Why?
|
Cyclosporine | 2 | 2008 | 239 | 0.110 |
Why?
|
Methylprednisolone | 2 | 2006 | 66 | 0.110 |
Why?
|
Decision Making | 1 | 2018 | 661 | 0.100 |
Why?
|
Protein Array Analysis | 1 | 2012 | 52 | 0.100 |
Why?
|
Cytomegalovirus Infections | 2 | 2006 | 146 | 0.100 |
Why?
|
B7-H1 Antigen | 1 | 2013 | 269 | 0.100 |
Why?
|
Heart Transplantation | 2 | 2006 | 720 | 0.090 |
Why?
|
Medical Futility | 1 | 2010 | 31 | 0.090 |
Why?
|
Mice, Inbred C57BL | 2 | 2008 | 3196 | 0.090 |
Why?
|
RNA, Viral | 2 | 2010 | 333 | 0.090 |
Why?
|
Intraoperative Period | 1 | 2010 | 90 | 0.090 |
Why?
|
Factor Analysis, Statistical | 1 | 2010 | 113 | 0.090 |
Why?
|
Gastroschisis | 1 | 2010 | 13 | 0.090 |
Why?
|
Reperfusion | 1 | 2010 | 32 | 0.090 |
Why?
|
Intestinal Volvulus | 1 | 2010 | 10 | 0.090 |
Why?
|
Transplantation | 1 | 2010 | 40 | 0.090 |
Why?
|
Short Bowel Syndrome | 1 | 2010 | 41 | 0.090 |
Why?
|
DNA, Viral | 1 | 2010 | 265 | 0.080 |
Why?
|
Bilirubin | 1 | 2009 | 130 | 0.080 |
Why?
|
Intestinal Diseases | 1 | 2010 | 79 | 0.080 |
Why?
|
Allografts | 2 | 2020 | 177 | 0.080 |
Why?
|
Hepatitis C, Chronic | 1 | 2010 | 127 | 0.080 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 44 | 0.080 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2010 | 79 | 0.080 |
Why?
|
Antiviral Agents | 2 | 2006 | 514 | 0.080 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2008 | 79 | 0.080 |
Why?
|
Calcineurin Inhibitors | 1 | 2008 | 56 | 0.080 |
Why?
|
Bile Duct Diseases | 1 | 2008 | 22 | 0.080 |
Why?
|
Workload | 1 | 2009 | 129 | 0.080 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 201 | 0.080 |
Why?
|
Intraoperative Complications | 1 | 2009 | 188 | 0.080 |
Why?
|
Interleukin-4 | 1 | 2008 | 130 | 0.080 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 453 | 0.080 |
Why?
|
Risk | 3 | 2019 | 660 | 0.080 |
Why?
|
ROC Curve | 1 | 2010 | 773 | 0.070 |
Why?
|
Quality of Life | 2 | 2006 | 1646 | 0.070 |
Why?
|
Population Surveillance | 1 | 2008 | 217 | 0.070 |
Why?
|
CD4-CD8 Ratio | 1 | 2006 | 18 | 0.070 |
Why?
|
Mice, Obese | 1 | 2006 | 43 | 0.070 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2006 | 61 | 0.070 |
Why?
|
Bezafibrate | 1 | 2006 | 5 | 0.070 |
Why?
|
Warm Ischemia | 1 | 2006 | 31 | 0.070 |
Why?
|
Major Histocompatibility Complex | 1 | 2006 | 83 | 0.070 |
Why?
|
Hepatic Encephalopathy | 1 | 2006 | 43 | 0.070 |
Why?
|
Polypropylenes | 1 | 2006 | 23 | 0.070 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 2006 | 20 | 0.070 |
Why?
|
Microcirculation | 1 | 2006 | 106 | 0.070 |
Why?
|
Homozygote | 1 | 2006 | 202 | 0.070 |
Why?
|
Multicenter Studies as Topic | 1 | 2006 | 155 | 0.070 |
Why?
|
Regional Blood Flow | 1 | 2006 | 198 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2012 | 1788 | 0.070 |
Why?
|
Leptin | 1 | 2006 | 105 | 0.070 |
Why?
|
Cytomegalovirus | 1 | 2006 | 78 | 0.070 |
Why?
|
Restriction Mapping | 1 | 2006 | 156 | 0.070 |
Why?
|
Metabolic Diseases | 1 | 2006 | 50 | 0.070 |
Why?
|
Blood Chemical Analysis | 1 | 2006 | 42 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2008 | 321 | 0.070 |
Why?
|
Models, Theoretical | 1 | 2009 | 489 | 0.070 |
Why?
|
Chimera | 1 | 2006 | 56 | 0.070 |
Why?
|
Glucose Intolerance | 1 | 2006 | 94 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2006 | 1220 | 0.070 |
Why?
|
Interleukin-10 | 1 | 2006 | 151 | 0.070 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2006 | 43 | 0.070 |
Why?
|
Psychology | 1 | 2005 | 24 | 0.070 |
Why?
|
Cricetinae | 1 | 2006 | 560 | 0.070 |
Why?
|
Herpesvirus 4, Human | 1 | 2006 | 119 | 0.070 |
Why?
|
Confidence Intervals | 1 | 2006 | 226 | 0.070 |
Why?
|
Up-Regulation | 1 | 2008 | 729 | 0.060 |
Why?
|
Heterozygote | 1 | 2006 | 372 | 0.060 |
Why?
|
Hypolipidemic Agents | 1 | 2006 | 99 | 0.060 |
Why?
|
Spleen | 1 | 2006 | 431 | 0.060 |
Why?
|
Organ Preservation | 1 | 2006 | 101 | 0.060 |
Why?
|
Long-Term Care | 1 | 2006 | 62 | 0.060 |
Why?
|
Mice, SCID | 1 | 2006 | 261 | 0.060 |
Why?
|
Linear Models | 1 | 2006 | 423 | 0.060 |
Why?
|
Disease Outbreaks | 1 | 2006 | 155 | 0.060 |
Why?
|
Reperfusion Injury | 1 | 2006 | 139 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2006 | 430 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2006 | 314 | 0.060 |
Why?
|
Drug Overdose | 1 | 2006 | 70 | 0.060 |
Why?
|
Diarrhea | 1 | 2006 | 182 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2006 | 105 | 0.060 |
Why?
|
Suicide, Attempted | 1 | 2006 | 131 | 0.060 |
Why?
|
Killer Cells, Natural | 1 | 2006 | 274 | 0.060 |
Why?
|
Transplantation, Autologous | 1 | 2006 | 340 | 0.060 |
Why?
|
Monocytes | 1 | 2006 | 217 | 0.060 |
Why?
|
Transplantation, Heterologous | 1 | 2006 | 371 | 0.060 |
Why?
|
Perioperative Care | 1 | 2006 | 167 | 0.060 |
Why?
|
Catheterization | 1 | 2006 | 238 | 0.060 |
Why?
|
Haplotypes | 1 | 2006 | 637 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2006 | 248 | 0.060 |
Why?
|
Postoperative Care | 1 | 2005 | 230 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 902 | 0.060 |
Why?
|
Species Specificity | 1 | 2006 | 684 | 0.060 |
Why?
|
Biomarkers | 1 | 2010 | 1754 | 0.060 |
Why?
|
Radiography | 1 | 2006 | 806 | 0.060 |
Why?
|
Gene Expression | 1 | 2008 | 1311 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2006 | 342 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2006 | 439 | 0.060 |
Why?
|
Insulin Resistance | 1 | 2006 | 363 | 0.060 |
Why?
|
Genetic Variation | 1 | 2010 | 1368 | 0.060 |
Why?
|
Alleles | 1 | 2006 | 1131 | 0.050 |
Why?
|
Chromatography, Liquid | 2 | 2014 | 105 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2006 | 389 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2006 | 836 | 0.050 |
Why?
|
Mass Spectrometry | 2 | 2014 | 193 | 0.050 |
Why?
|
Cytokines | 1 | 2006 | 801 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2006 | 387 | 0.050 |
Why?
|
Portacaval Shunt, Surgical | 1 | 2001 | 9 | 0.050 |
Why?
|
Apoptosis | 1 | 2008 | 1715 | 0.050 |
Why?
|
Cardiac Surgical Procedures | 1 | 2006 | 473 | 0.050 |
Why?
|
Area Under Curve | 1 | 2021 | 333 | 0.050 |
Why?
|
Cells, Cultured | 1 | 2006 | 2873 | 0.050 |
Why?
|
Recurrence | 3 | 2012 | 1168 | 0.050 |
Why?
|
Biopsy | 2 | 2010 | 1187 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2006 | 1401 | 0.050 |
Why?
|
Advance Care Planning | 1 | 2020 | 43 | 0.040 |
Why?
|
Shock | 1 | 2020 | 44 | 0.040 |
Why?
|
Rats | 1 | 2006 | 4032 | 0.040 |
Why?
|
Cell Differentiation | 1 | 2006 | 1513 | 0.040 |
Why?
|
Machine Learning | 1 | 2021 | 241 | 0.040 |
Why?
|
Cadaver | 1 | 2019 | 185 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2006 | 2340 | 0.040 |
Why?
|
Venous Thrombosis | 1 | 2001 | 250 | 0.040 |
Why?
|
Erythrocyte Count | 1 | 2018 | 22 | 0.040 |
Why?
|
Plasma | 1 | 2018 | 51 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2006 | 2399 | 0.040 |
Why?
|
Acyclovir | 1 | 1997 | 107 | 0.040 |
Why?
|
Azathioprine | 1 | 1997 | 125 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 3433 | 0.040 |
Why?
|
Disease Progression | 2 | 2012 | 1489 | 0.030 |
Why?
|
Acute Disease | 1 | 1997 | 838 | 0.030 |
Why?
|
Glucocorticoids | 1 | 1997 | 358 | 0.030 |
Why?
|
Mutation | 1 | 2006 | 4092 | 0.030 |
Why?
|
Ions | 1 | 2014 | 75 | 0.030 |
Why?
|
Sampling Studies | 1 | 2012 | 72 | 0.030 |
Why?
|
Thrombophilia | 1 | 2012 | 22 | 0.030 |
Why?
|
Models, Animal | 1 | 2013 | 276 | 0.030 |
Why?
|
Hospitals, Pediatric | 1 | 2012 | 109 | 0.020 |
Why?
|
Reference Values | 1 | 2012 | 665 | 0.020 |
Why?
|
Serum | 1 | 2010 | 25 | 0.020 |
Why?
|
Hemorrhage | 1 | 2012 | 276 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 307 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 360 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2012 | 333 | 0.020 |
Why?
|
Genotype | 2 | 2008 | 1867 | 0.020 |
Why?
|
Health Care Rationing | 1 | 2010 | 83 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2012 | 455 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2010 | 205 | 0.020 |
Why?
|
Cytochrome P-450 CYP2C8 | 1 | 2008 | 3 | 0.020 |
Why?
|
8,11,14-Eicosatrienoic Acid | 1 | 2008 | 12 | 0.020 |
Why?
|
Arachidonic Acid | 1 | 2008 | 63 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2008 | 114 | 0.020 |
Why?
|
Overweight | 1 | 2009 | 117 | 0.020 |
Why?
|
Demography | 1 | 2008 | 181 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2012 | 2019 | 0.020 |
Why?
|
Sex Factors | 1 | 2010 | 1062 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2010 | 546 | 0.020 |
Why?
|
Kinetics | 1 | 2008 | 1528 | 0.020 |
Why?
|
Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 1997 | 1212 | 0.010 |
Why?
|